Antagonizing the ERβ-mediated signaling pathway in the presence or absence of E2 is not promising as ERβ is known to counteract the proliferative responses of ERα involved in estrogen-related cancers, osteoporosis, and cardiovascular diseases. Here, ESR2 is linked to cardiovascular disorder.